Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders

Current Opinion in Investigational Drugs

Volumn 10, Issue 7, 2009, Pages 691-701

  Hardeland, Rüdiger ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMITRIPTYLINE; BMS 214778; IMIPRAMINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; TASIMELTEON; UNCLASSIFIED DRUG; VEC 162; VSF 173;

AREA UNDER THE CURVE; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSOMNIA; JET LAG; LATENT PERIOD; MAJOR DEPRESSION; NAUSEA; NONHUMAN; PAIN; RECEPTOR DENSITY; REVIEW; SHIFT WORKER; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; SUPRACHIASMATIC NUCLEUS; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ANIMALS; BENZOFURANS; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; DRUGS, INVESTIGATIONAL; HUMANS; MELATONIN; MOLECULAR STRUCTURE; PATENTS AS TOPIC; RECEPTORS, MELATONIN; SLEEP DISORDERS, CIRCADIAN RHYTHM; SLEEP INITIATION AND MAINTENANCE DISORDERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68249105543     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. 443730 The sleep switch: Hypothalamic control of sleep and wakefulness. Saper CB, Chou TC, Scammell TE TRENDS NEUROSCI. 2001 2412 726-731
2. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman TA, Pasteau V, Rivet JM, Cussac D J PHARMACOL EXP THER. 2003 3063 954-964
3. 2C antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. Loo H, Hale A, D'haenen H INT CLIN PSYCHOPHARMACOL. 2002 175 239-247
4. Evolution of a manufacturing route for a highly potent drug candidate. Singh AK ACS. 2005 229Abs MEDI 576
5. 2Creceptor blockade. Millan MJ, Brocco M, Gobert A, Dekeyne A PSYCHOPHARMACOLOGY. 2005 1774 1-12
6. Company website. Vanda Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE. 2006 January 12
7. Vanda Pharmaceuticals reports first quarter 2006 financial results. Vanda Pharmaceuticals Inc PRESS RELEASE. 2006 May 18
8. 2 receptor agonist. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M NEUROPHARMACOLOGY. 2005 482 301-310
9. Melatonin as a chronobiotic. Arendt J, Skene DJ SLEEP MED REV. 2005 91 25-39
10. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Liu C, Weaver D R, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM NEURON. 1997 191 91-102
11. 1b melatonin receptor. Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM, Weaver DR MOL CELL BIOL. 2003 233 1054-1060
12. 2 melatonin receptors in mammals. Dubocovich ML, Markowska M ENDOCRINE. 2005 272 101-110
13. NCT00490945: Safety and efficacy of VEC-162 on circadian rhythm in healthy adult volunteers. CLINICALTRIALS.GOV. 2007 June 22
14. Sleep and sleep disturbances: Biological basis and clinical implications. Zisapel N CELL MOL LIFE SCI. 2007 6410 1174-1186
15. WO-09825606: Benzodioxole, benzofuran, dihydrobenzo- furan, and benzodioxane melatonergic agents. Catt JD, Johnson G, Keavy DJ, Mattson RJ, Parker MF, Takaki KS, Yevich JP WORLD PATENT. 1998 June 18 Discloses the structure of tasimelteon and numerous related compounds, and presents comprehensive synthesis and SAR data of tasimelteon and several comparable substances.
16. 866464 Evidence of agomelatine's antidepressant efficacy: The key points. Eser D, Baghai TC, Moller HJ INT CLIN PSYCHOPHARMACOL. 2007 22Suppl 2 S15-S19
17. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. Vachharajani NN, Yeleswaram K, Boulton DW J PHARM SCI. 2003 924 760-772 Describes preclinical data on the main metabolites of tasimelteon. Also provides detailed information about the single and multiple dose pharmacokinetics of the drug in rats and in monkeys.
18. 888261 Form 10-K 2007 - Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Inc FORM 10-K. 2008 March 13
19. Phase III data show Vanda Pharmaceuticals' tasimelteon (VEC-162) significantly improves sleep in patients with chronic insomnia. Vanda Pharmaceuticals Inc PRESS RELEASE. 2008 June 26 Provides data on a phase III clinical trial, conducted in patients diagnosed with chronic primary insomnia. Efficacy data are presented demonstrating improvements in LPS and LNA at 20 and 50 mg of tasimelteon when compared with placebo.
20. 946900 Ramelteon: A novel approach in the treatment of insomnia. Reynoldson JN, Elliott ESR, Nelson LA ANN PHARMACOTHER. 2008 429 1262-1271
21. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomised controlled multicentre trials. Rajaratnam SMW, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB LANCET. 2009 3739662 482-491 Presents data from phase II and phase III clinical trials, demonstrating that tasimelteon exhibits circadian phase shifting and soporific effects after 5-h advance shifts, thus indicating the potential usefulness of the drug for the treatment of jet lag, shift work and, perhaps, circadian rhythm sleep disorders. Adverse effects were mild and in the range of those observed with placebo.
22. 967913 Let there be sleep-On time. Cardinali D, Golombek D LANCET. 2009 3739662 439-441
23. Melatonin agonist VEC-162 improves sleep onset and maintenance in a model of transient insomnia. Birznieks G, Scott C, Baroldi P, Polymeropoulos M, Roth T SLEEP. 2007 30Suppl S Abs 0773
24. The melatonin agonist VEC-162 immediately phase-advances the human circadian system. Rajaratnam SM, Polymeropoulos MH, Fischer DM, Scott CH, Birznieks G, Klerman EB SLEEP. 2006 29Suppl Abs 0159
25. Catalytic asymmetric synthesis of a melatonin antagonist; synthesis and process optimisation. Scott JW ACS. 2002 223Pt 2 Abs ORGN 186
26. Identification ofin vitroandin vivometabolites of BMS-214778 in monkeys by ion trap LC/MS and LC/NMR. Zhu M, Mitroka J, Shaw AA, Luke GM, Vachharajani N, Kripalani KJ DRUG METAB REV. 2000 32Suppl 2 Abs 248
27. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Rivara S, Mor M, Bedini A, Spadoni G, Tarzia G CURR TOP MED CHEM. 2008 811 954-968
28. The melatonin rhythm: Both a clock and a calendar. Reiter RJ EXPERIENTIA. 1993 498 654-664
29. Melatonin: Nature's most versatile biological signal?Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R FEBS J. 2006 27313 2813-2838
30. Melatonin, hormone of darkness and more: Occurrence, control mechanisms, actions and bioactive metabolites. Hardeland R CELL MOL LIFE SCI. 2008 6513 2001-2018
31. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Reppert SM, Weaver DR, Ebisawa T NEURON. 1994 135 1177-1185
32. Melatonin receptors: Molecular biology of a new family of G protein-coupled receptors. Reppert SM J BIOL RHYTHMS. 1997 126 528-531
33. Melatonin receptor genes. Kokkola T, Laitinen JT ANN MED. 1998 301 88-94
34. Melatonin: Signaling mechanisms of a pleiotropic agent. Hardeland R BIOFACTORS. 2009 352 183-192
35. 2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML AM J PHYSIOL - CELL PHYSIOL. 2001 2801 C110-C118
36. Drug Insight: The use of melatonergic agonists for the treatment of insomnia - Focus on ramelteon. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP NAT CLIN PRACT NEUROL. 2007 34 221-228
37. Melatonin receptors: Role on sleep and circadian rhythm regulation. Dubocovich ML SLEEP MED. 2007 8Suppl 3 34-42
38. Melatonergic drugs in clinical practice. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP ARZNEIMITTEL- FORSCH. 2008 581 1-10
39. Hypothalamic regulation of sleep and circadian rhythms. Saper CB, Scammell TE, Lu J NATURE. 2005 4377063 1257-1263
40. Neurobiology of the sleep-wake cycle: Sleep architecture, circadian regulation, and regulatory feedback. Fuller PM, Gooley JJ, Saper CB J BIOL RHYTHMS. 2006 216 482-493
41. Insomnia causes, consequences, and therapeutics: An overview. Drake CL, Roehrs T, Roth T DEPRESSION ANXIETY. 2003 184 163-176
42. National Institutes of Health State of the Science Conference: Statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. National Institutes of Health SLEEP. 2005 289 1049-1057
43. Circadian rhythm sleep disorders. Lu BS, Zee PC CHEST. 2006 1306 1915-1923
44. Circadian rhythms in the CNS and peripheral clock disorders: Human sleep disorders and clock genes. Ebisawa T J PHARMACOL SCI. 2007 1032 150-154
45. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora RN, Boehlecke B, Brown T, Chesson AL Jr, Kapur V, Maganti R, Owens J et al SLEEP. 2007 3011 1445-1459
46. Circadian rhythm sleep disorders following mild traumatic brain injury. Ayalon L, Borodkin K, Dishon L, Kanety H, Dagan Y NEUROLOGY. 2007 6814 1136-1140
47. The human circadian clock and aging. Hofman MA CHRONOBIOL INT. 2000 173 245-259
48. Living by the clock: The circadian pacemaker in older people. Hofman MA, Swaab DF AGEING RES REV. 2006 51 33-51 1000943 Melatonin and aging. Karasek M, Reiter RJ NEUROENDOCRINOL LETT. 2002 23Suppl 1 14-16
49. Melatonin, human aging, and age-related diseases. Karasek M EXP GERONTOL. 2004 3911-12 1723-1729
50. Jet-lag and shift work: (2). Therapeutic use of melatonin. Arendt J J R SOC MED. 1999 928 402-405
51. Use of melatonin in the treatment of phase shift and sleep disorders. Skene DJ, Lockley SW, Arendt J ADV EXP MED BIOL. 1999 46779-84
52. Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Skene DJ, Arendt J SLEEP MED. 2007 86 651-655
53. Circadian genes, rhythms and the biology of mood disorders. McClung CA PHARMACOL THER. 2007 1142 222-232
54. The phase shift hypothesis for the circadian component of winter depression. Lewy AJ, Rough JN, Songer JB, Mishra N, Yuhas K, Emens JS DIALOGUES CLIN NEUROSCI. 2007 93 291-300
55. Seasonal affective disorder: A clinical update. Westrin A, Lam RW ANN CLIN PSYCHIATY. 2007 194 239-246
56. Melatonin and human chronobiology. Lewy AJ COLD SPRING HARBOR SYMP QUANT BIOL. 2007 72623-636
57. Melatonin in mood disorders. Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR, Parry B, Cardinali DP WORLD J BIOL PSYCHIATRY. 2006 73 138-151
58. The role of circadian clock genes in mental disorders. Lamont EW, Legault-Coutu D, Cermakian N, Boivin DB DIALOGUES CLIN NEUROSCI. 2007 93 333-342
59. Dysthymia: Clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. Brunello N, Akiskal H, Boyer P, Gessa GL, Howland RH, Langer SZ, Mendlewicz J, Paes de Souza M, Placidi GF, Racagni G, Wessely S J AFFECT DISORD. 1999 521-3 275-290
60. Could agomelatine be the ideal antidepressant?Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti MJ EXPERT REV NEUROTHERAPEUTICS. 2006 611 1595-1608
61. Pathophysiology of depression: Role of sleep and the melatonergic system. Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, Cardinali DP PSYCHIATRY RES. 2009 1653 201-214
62. The basic physiology and pathophysiology of melatonin. Claustrat B, Brun J, Chazot G SLEEP MED REV. 2005 91 11-24
63. US-5856529: Benzofuran and dihydrobenzofuran melatonergic agents. Catt JD, Johnson G, Keavy DJ, Mattson RJ, Parker MF, Takaki KS, Yevich JP US PATENT. 1999 January 05
64. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT 1 and MT 2 melatonin receptor agonist indicated for treatment of insomnia. Karim A, Tolbert D, Cao C J CLIN PHARMACOL. 2006 462 140-148
65. Biphasic responses in synergistic interactions. Hodgson E, Ryu DY, Adams N, Levi PE TOXICOLOGY. 1995 1052-3 211-216
66. Regulation of cytochrome P-450 isozymes CYP1A1, CYP1A2 and CYP2B10 by three benzodioxole compounds. Ryu DY, Levi PE, Hodgson E CHEM BIOL INTERACT. 1995 963 235-247
67. New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): Studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. Staack RF, Maurer HH J MASS SPECTROM. 2004 393 255-261
68. Safrole: Its metabolism, carcinogenicity and interactions with cytochrome P-450. Ioannides C, Delaforge M, Parke DV FOOD COSMET TOXICOL. 1981 195 657-666
69. Flavonoids and alkenylbenzenes: Mechanisms of mutagenic action and carcinogenic risk. Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM MUTAT RES. 2005 5741-2 124-138
70. Actions of melatonin, its structural and functional analogs in the central nervous system and the significance of metabolism. Hardeland R, Poeggeler B CENT NERV SYST AGENTS MED CHEM. 2007 7289-303
71. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Pandi-Perumal SR, Trakht I, Spence DW, Srinivasan V, Dagan Y, Cardinali DP NAT CLIN PRACT NEUROL. 2008 48 436-447
72. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P SLEEP MED. 2006 74 312-318
73. Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Raghavendra V, Kaur G, Kulkarni SK EUR NEUROPSYCHOPHARMACOL. 2000 106 473-481
74. Acute antidepressant-like and antianxiety-like effects of tryptophan in mice. Wong PT, Ong YP PHARMACOLOGY. 2001 623 151-156
75. Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: A double-blind, randomized, placebo-controlled study. Caumo W, Levandovski R, Hidalgo MP J PAIN. 2009 101 100-108
76. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Ismail SA, Mowafi HA ANESTH ANALG. 2009 1084 1146-1151
77. Melatonin does not reduce anxiety more than placebo in the elderly undergoing surgery. Capuzzo M, Zanardi B, Schiffino E, Buccoliero C, Gragnaniello D, Bianchi S, Alvisi R ANESTH ANALG. 2006 1031 121-123
78. Efficacy of agomelatine, a MT 1/MT 2 receptor agonist with 5-HT 2c antagonistic properties, in major depressive disorder. Olie JP, Kasper S INT J NEUROPSYCHOPHARMACOL. 2007 105 661-673
79. Melatonin beyond its classical functions. Hardeland R, Poeggeler B OPEN PHYSIOL J. 2008 11-23
80. International classification of sleep disorders: Diagnostic and coding manual. American Academy of Sleep Medicine INTERNATIONAL CLASSIFICATION OF SLEEP DISORDERS: DIAGNOSTIC AND CODING MANUAL. 2005 2nd Edition
81. Diagnostic and statistical manual of mental disorders. American Psychiatric Association DSM-IV: DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS. 2000 4th Edition
82. Assessment report for Circadin. European Agency for the Evaluation of Medicinal Products COMPANY PUBLICATION. 2007 July 10
83. Form 10-K 2008 - Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Inc FORM 10-K. 2009 March 11
84. Form 10-K 2006 - Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Inc FORM 10-K. 2007 March 16
85. US-6737431: Benzoxazole derivatives as novel melatonergic agents. Takaki KS, Sun LQ, Johnson G, Bertenshaw SR, Denhart D, Chen J US PATENT. 2004 May 18
86. US-5596019: N-acyl-cycloalkylamine derivatives as melatonergics. Mattson RJ, Keavy DJ, Parker MF, Johnson G US PATENT. 1997 January 21
87. WO-2006116136: Dihydrobenzofuran derivatives and uses thereof. Stack GP, Gross JL WORLD PATENT. 2006 November 02
88. 1002421 US-5753709: N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics. Keavy DJ, Parker MF, Mattson RJ, Johnson G US PATENT. 1998 May 19
89. US-6214869: Heterocyclic cis cyclopropane derivatives as melatonergic agents. Chen J, Dextraze P, Dodier M, Takaki KS US PATENT. 2001 April 10
90. WO-2007137247: Treatment for depressive disorders. Birznieks G, Phadke D, Polymeropoulos MH WORLD PATENT. 2007 November 29Provides preclinical data on the effects of tasimelteon in animal models of despair.
91. 1002764 WO-2007137244: Melatonin agonist treatment. Birznieks G, Phadke D, Polymeropoulos MH WORLD PATENT. 2007 November 29
92. Pharmacotherapy of insomnia: Focus on zolpidem extended release. Monti JM, Spence DM, Pandi-Perumal SR, Langer SZ, Hardeland R CLIN MED: THER. 2009 1123-140
93. The role of melatonin in the immuno-neuro-psychology of mental disorders. Maldonado MD, Perez-San-Gregorio MA, Reiter RJ RECENT PAT CNS DRUG DISCOV. 2009 41 61-69
94. WO-2009036257: Methods for the diagnosis and treatment of sleep disorders - Comprising the prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype. Lavedan C, Polymeropoulos M, Birznieks G WORLD PATENT. 2009 March 19
95. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Erman M, Seiden D, Zammit G, Sainati S, Zhang J SLEEP MED. 2006 71 17-24
96. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X J CLIN SLEEP MED. 2008 45 456-461
97. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Zee P, Richardson G, Wang-Weigand S ANN MEET SOC RES BIOL RHYTHMS. 2008 20Abs 18
98. Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. Kasper S, Hamon M WORLD J BIOL PSYCHIATRY. 2009 102 117-126
99. General form of registration statement: Initial statement. Vanda Pharmaceuticals Inc FORM S-1. 2005 December 29